FGI Industries (NASDAQ:FGI – Get Free Report) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.
Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of FGI Industries in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce”.
Read Our Latest Stock Analysis on FGI
FGI Industries Trading Down 7.7%
FGI Industries (NASDAQ:FGI – Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.30). FGI Industries had a negative net margin of 2.07% and a negative return on equity of 3.99%. The company had revenue of $31.00 million during the quarter, compared to analysts’ expectations of $32.66 million. FGI Industries has set its FY 2025 guidance at EPS. As a group, equities analysts predict that FGI Industries will post -0.08 earnings per share for the current fiscal year.
About FGI Industries
FGI Industries ltd. supplies kitchen and bath products in the United States, Canada, Europe, and internationally. The company sells sanitaryware products, such as toilets, sinks, pedestals, and toilet seats; wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry, medicine cabinets, and other storage systems; shower systems; and customer kitchen cabinetry and other accessory items under the Foremost, avenue, contrac, Jetcoat, rosenberg, and Covered Bridge Cabinetry brand names.
Recommended Stories
- Five stocks we like better than FGI Industries
- How to Use the MarketBeat Excel Dividend Calculator
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Compound Interest and Why It Matters When Investing
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Conference Calls and Individual Investors
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for FGI Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FGI Industries and related companies with MarketBeat.com's FREE daily email newsletter.